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are equipments or iSTAT for Glucose, BUN, Bilirubin, lactate and
lood gas analysis. Disposable Digital oxymeters can be used for
arly detection of hypoxia at affordable price.
Another milestone is the recent evidence of Artesunate as supe-
iod toquinine for better survival rate (AQUAMATandSEAQUAMAT
tudy)
Use of blood transfusion has not yet been studied conclusively,
ut recent reports indicate that Erythropheresis has a promising
ossibility. Use of albumin has not been established. Bolus ﬂuid
herapy was shown to be deleterious.
Weconducteda studyonuseof anti-oedemameasure (mannitol
n cerebralmalaria) and the results strongly contraindicated its use.
Similarly caution should be taken in using Enteral therapy in
omatose patients and frequent use of Central venous catheters.
The mortality can be inﬂuenced by early Renal replacement
herapy. Use of recent biomarkers to detect Acute Kidney Injury
arly for intervention may hold the key in coming years. (viz. NGAL
tc)
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ovel resources to fund health enterprises and develop new
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. Waldvogel
Director, Executive Board, WKD, Geneva, Switzerland
Development of novel drug entities and their adequate dis-
ribution to patients in diverse social and geographical settings
re amongst the formidable challenges to science, industry, gov-
rnmental agencies and health organizations. Both processes are
xtremely complex, characterized by many hurdles and poor
fﬁciency, due to lack of human motivation of administrative col-
aboration and of ﬁnancial resources. This presentation will focus
rimarily on a better distribution and usage of the presently avail-
ble ﬁnancial resources.
Drug development is a process which ﬂows from preclinical
esearch (target identiﬁcation, toxicity, pharmakokinetics) tophase
-3 clinical testing (dose ﬁnding, proof of concept and pivotal tri-
ls), and ﬁnally to acceptance by the regulatory authorities. From
0’000 initial compounds, only 10 will lead to clinical trials and
bout 2 will eventually reach the market. The costs of such a pro-
ess are considerable, in the range of 800 M US$ in out-of-pocket
xpenses and require new modes of risk mitigation. Between 2006
nd 2010, 10 large corporate and 10 large traditional venture funds
ave led this enterprise, totalling more than 700 deals, within a
ulti billion US$ European and US market. The investment strat-
gy, results and perspectives of one of the top funds, the Novartis
enture Funds, will be presented and discussed.
At the other end of the pipeline, novel or standard products have
o reach the communities whether afﬂuent or in ﬁnancial need.
heir distribution and the organization of adequate health policies
or the poor in developing countries represent another, still largely
nmet world challenge. It entails helping those with no or low
ncome to have access to loans and to appropriate ﬁnancial services
nd from there to adequate health care systems The microﬁnance
ovement, created in 1970 by Yunus in Bangladesh and which hasnfectious Diseases 16S (2012) e2–e157
expanded rapidly worldwide, is one of the promising ﬁnancia and
economic strategies tomeet this goal. There are presently 25 billion
US$ at work in the microﬁnance movement, for an estimated 250
billion US$ potential. Principles, boundaries criticisms and outlook
of this new ﬁnancial system will be presented, taking Symbiotics
Inc. – one of the large institutions providing such services – as an
example.
Adequate utilization of the presently available resources –
whether by ﬁnancing innovation or providing acceptable services
to the poor - should allow with time a better access of everyone to
human health needs.
http://dx.doi.org/10.1016/j.ijid.2012.05.111
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Clinical research in the context of rapidly emerging public
health threats
J. Farrar
Centre For Tropical Diseases, Ho Chi Minh City, Viet Nam
A key lesson from a series of recent outbreaks of emerging
pathogens of global public health importance including SARS-CoV,
highly pathogenic avian inﬂuenza A (H5N1) virus, Nipah virus and
the 2009H1N1 virus pandemicwas thatmounting clinical research
in response to a rapidly emerging infectious disease is extremely
challenging and often delayed. During these events, important
pathogenesis and clinicalmanagementdata camemostly fromsites
that were already undertaking related clinical studies including
those on inter-pandemic inﬂuenza (e.g., SEAICRN, Institute Pas-
teur Networks, Chinese University of Hong Kong, and University
of Hong Kong) or from established national or regional research
networks such as the Canadian and Australia/New Zealand Criti-
cal Care Trials Group. However there was very little cross-border
coordination, unlike that which now exists in epidemiology and to
an extent in virology and genomics. The clinical research response
was cumbersome and slow despite years of global preparations
for a potentially devastating inﬂuenza pandemic of avian origin
or the next SARS-like outbreak. Although observational registries
were mobilized, initiatives to launch randomized controlled trials
or more sophisticated biologic studies generally missed the ini-
tial waves of the 2009 H1N1 pandemic and in many cases failed
to enrol sufﬁcient numbers of patients across the entire clinical
spectrum of disease into studies, even during subsequent waves.
During the 2009 H1N1 virus pandemic the efforts to prepare for
a respiratory disease outbreak allowed a reasonably rapid and
coordinated response on epidemiologic and diagnostic aspects of
disease but failed in the timely conduct of clinical research aimed
at improving patient management or understanding pathogenesis.
The failure to have coordinated, comparable data on clinical man-
agement and pathogenesis of 2009 H1N1 virus infection meant
that we missed the opportunity to improve patient outcomes.
Indeed this has been a problem in almost all epidemics over the
last decade (Nipah, SARS, H5N1, and in outbreaks of VHF) with
very little research aimed at improving clinical management or
understanding pathogenesis. This has demonstrated that unless
something is done now to change the barriers faced in 2009, the
next inﬂuenza (or other) outbreak will result in a similar missed
